{
    "organizations": [],
    "uuid": "2dd206874835c5d20fcf7daf52923b94f6b750c1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ligand-pharmaceuticals-entered-com/brief-ligand-pharmaceuticals-entered-commercial-platform-license-agreement-with-ksq-therapeutics-idUSFWN1SH0Q4",
    "ord_in_thread": 0,
    "title": "BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Ligand Pharmaceuticals Inc:\n* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING\n* LIGAND PHARMACEUTICALS INC - KSQ TO BE ABLE TO USE COâ€™S FULL OMNIAB PLATFORM TO DISCOVER ANTIBODIES\n* LIGAND - RECEIVED UPFRONT PAYMENT, ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT & REGULATORY MILESTONE PAYMENTS AMONG OTHERS\n* LIGAND PHARMACEUTICALS INC - KSQ TO BE RESPONSIBLE FOR ALL COSTS RELATED TO ITS ANTIBODY DEVELOPMENT PROGRAM Source text: [ bit.ly/2rzArcO ] Further company coverage:\n ",
    "published": "2018-05-10T18:49:00.000+03:00",
    "crawled": "2018-05-11T12:53:04.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "ligand",
        "pharmaceutical",
        "inc",
        "ligand",
        "pharmaceutical",
        "may",
        "entered",
        "commercial",
        "platform",
        "license",
        "agreement",
        "ksq",
        "therapeutic",
        "inc",
        "sec",
        "filing",
        "ligand",
        "pharmaceutical",
        "inc",
        "ksq",
        "able",
        "use",
        "co",
        "full",
        "omniab",
        "platform",
        "discover",
        "antibody",
        "ligand",
        "received",
        "upfront",
        "payment",
        "eligible",
        "receive",
        "annual",
        "platform",
        "access",
        "payment",
        "development",
        "regulatory",
        "milestone",
        "payment",
        "among",
        "others",
        "ligand",
        "pharmaceutical",
        "inc",
        "ksq",
        "responsible",
        "cost",
        "related",
        "antibody",
        "development",
        "program",
        "source",
        "text",
        "company",
        "coverage"
    ]
}